Voor de voormalige CRUCELL aandeelhouders: Minstens 8 jaar oud:
Crucell scientists focus on the discovery and development of transformational immunization products to protect people worldwide against major health threats. Here are just some examples of what we are doing to bring meaningful innovation to global health.
Ebola and Marburg
We are collaborating with international health organizations including WHO and NIAID, and other key stakeholders, governments and public health authorities on the clinical testing, development, production and distribution of the vaccine regimen. The vaccine regimen, which was discovered in a collaborative research program with the National Institutes of Health (NIH), combines a Crucell preventive vaccine with that of Bavarian Nordic (OMX: BAVA), a biotechnology company based in Denmark. This combination vaccine regimen has shown promising results in preclinical studies, and is now planned to be tested for safety and immunogenicity in healthy volunteers in Europe, the USA and Africa starting early January. The company is targeting production of more than one million doses of the vaccine regimen in 2015 – 250,000 of which are expected to be released for broad application in clinical trials by May 2015.